CDKN2A and BAP1 germline mutations predispose to melanoma and mesothelioma

1   *CDKN2A* and *BAP1* germline mutations predispose to melanoma and mesothelioma

2   Betti M[1], Aspesi A[1], Biasi A[1], Casalone E[2,3], Ferrante D[4], Ogliara P[5],Gironi LC[6], Giorgione R[6],

3   Farinelli P[6], Grosso F[7], Libener R[8], Rosato S[9], Turchetti D[10], Maffè A[11], Casadio C[12], Ascoli V[13],

4   Dianzani C[14], Colombo E[6], Piccolini E[15], Pavesi M[16], Miccoli S[10], Mirabelli D[17,18], Bracco C[5],

5   Righi L[19], Boldorini R[20], Papotti M[21], Matullo G[2,3], Magnani C[4,18],Pasini B[2,5,^], Dianzani I[1,18,^,*]

6   [1]Department of Health Sciences, University of Piemonte Orientale, Novara, Italy

7   [2]Department of Medical Sciences, University of Turin, Turin, Italy

8   [3]Human Genetics Foundation, HuGeF, Turin, Italy

9   [4]CPO-Piemonte and Unit of Medical Statistics and Epidemiology, Department of Translational Medicine, University of Piemonte
10   Orientale, Novara, Italy

11   [5]Medical Genetics Unit, AOU Città della Salute e della Scienza, Turin, Italy

12   [6]Dermatology Clinic, Department of Clinical and Experimental Medicine, University of Piemonte Orientale, Novara, Italy

13   [7]Division of Medical Oncology, SS.Antonio e Biagio General Hospital, Alessandria, Italy

14   [8]Pathology Unit, SS.Antonio e Biagio General Hospital, Alessandria, Italy

15   [9]Department of Obstetric, Gynecologic and Pediatric, Section of Clinical Genetics, Arcispedale S. Maria Nuova-IRCCS, Reggio
16   Emilia, Italy

17   [10]Medical Genetics, Policlinico Sant'Orsola-Malpighi, Bologna, Italy

18   [11]Molecular Genetics and Biology Unit, Santa Croce e Carle Hospital, Cuneo, Italy

19   [12]Thoracic Surgery Unit, Azienda Ospedaliero-Universitaria Maggiore della Carità, Novara, Italy

20   [13]Department of Radiological, Oncological and Pathological Sciences, Sapienza University, Rome, Italy

21   [14]Department of Dermatology, Campus Biomedico, University of Rome, Rome, Italy

22   [15]Pneumology Unit, Santo Spirito Hospital, Casale Monferrato, Italy

23   [16]Pathological Anatomy Unit, Santo Spirito Hospital, Casale Monferrato, Italy

24   [17]Unit of Cancer Epidemiology, CPO-Piemonte and University of Turin, Turin, Italy

25   [18]Interdepartmental Center for Studies on Asbestos and other Toxic Particulates "G. Scansetti", University of Turin, Turin, Italy

26   [19]Department of Oncology, University of Turin at San Luigi Hospital, Orbassano, Turin, Italy

27   [20]Department of Health Sciences, Section of Pathological Anatomy, University of Piemonte Orientale, Novara, Italy

28   [21]Department of Oncology, University of Turin, AOU Città della Salute e della Scienza di Torino, Turin, Italy

29
30   ^ Barbara Pasini and Irma Dianzani contributed equally to this work.

31
32
33
34
35   *Corresponding author:
36   Irma Dianzani
37   Department of Health Sciences, University of Piemonte Orientale
38   Via Solaroli 17, 28100 Novara, Italy
39   E-mail: irma.dianzani@med.uniupo.it

40

1

41 **Abstract**

42 *BAP1* germline mutations predispose to a cancer predisposition syndrome that includes
43 mesothelioma, cutaneous melanoma, uveal melanoma and other cancers. This co-occurrence
44 suggests that these tumors share a common carcinogenic pathway. To evaluate this hypothesis, we
45 studied 40 Italian families with mesothelioma and/or melanoma. The probands were sequenced for
46 *BAP1*and for the most common melanoma predisposition genes (i.e. *CDKN2A*, *CDK4*, *TERT*, *MITF*
47 and *POT1*) to investigate if these genes may also confer susceptibility to mesothelioma.

48 In two out of six families with both mesothelioma and melanoma we identified either a germline
49 nonsense mutation (c.1153C>T, p.Arg385*) in *BAP1* or a recurrent pathogenic germline mutation
50 (c.301G>T, p.Gly101Trp) in *CDKN2A*.

51 Our study suggests that *CDKN2A*, in addition to *BAP1*, could be involved in the melanoma and
52 mesothelioma susceptibility, leading to the rare familial cancer syndromes. It also suggests that
53 these tumors share key steps that drive carcinogenesis and that other genes may be involved in
54 inherited predisposition to malignant mesothelioma and melanoma.

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

2

1. Introduction

Monogenic cancer predisposition syndromes provide key insights into the complex stepwise mechanisms of carcinogenesis. Identified in 2011, the inherited cancer predisposition syndrome caused by germline mutations in the tumor suppressor gene *BAP1* (BRCA1-Associated Protein 1) has shed light for the first time on monogenic malignant mesothelioma (MM) predisposition [1-6]. However, the *BAP1* syndrome spectrum (MIM#614327) includes also other tumors, e.g. cutaneous melanoma (CM), uveal melanoma (UM) [7-18], epithelioid atypical Spitz tumors [19], lung adenocarcinoma, meningiomas [20], neuroendocrine tumors, breast cancer, cholangiocarcinoma, prostate cancer, paraganglioma, renal cell carcinomas [12,21-23] and basal cell carcinoma (BCC) [24-25]. Recently, our group showed an additional tumor type associated with *BAP1* germlinemutation, the rare mucoepidermoid carcinoma [26].

So far 67 families with the *BAP1* cancer predisposition syndrome and 56*BAP1* germline mutations have been described [5-6,15-18].

More information is needed to ascertain the phenotype of this syndrome, including the evolution of malignant tumors and their response to therapy. Information gained on other cancer-prone syndromes has shown that peculiar response to treatment should influence treatment choice in carriers of germline mutations as compared with sporadic tumors (for example, breast and ovarian cancer due to *BRCA1* and *BRCA2*) [27].

Thus, to better characterize the *BAP1* cancer predisposition syndrome, we identified and studied 40 Italian families with a suspected predisposition for mesothelioma and/or melanoma. *BAP1* gene was sequenced in a representative subject of each family and the same index cases were also studied for the most common melanoma predisposition genes (i.e. *CDKN2A*, *CDK4*, *TERT*, *MITF*, *POT1*) [28-29] to investigate if these genes may also confer susceptibility to mesothelioma.

2. Materials and Methods

2.1 Probands and Families

We focused only on melanoma and mesothelioma among the *BAP1*-related tumors because of our clinical and epidemiological expertise focused on these tumors.

The probands with melanoma were collected from the melanoma databases of the Dermatology Clinic, AOU Maggiore della Carità (Novara), the Medical Genetics Unit, AOU Città della Salute e della Scienza (University of Turin), the Medical Genetics Unit, Policlinico S.Orsola-Malpighi

3

101 (University of Bologna), the Clinical Genetics Unit of the Department of Obstetric, Gynecologic

102 and Pediatric, Arcispedale S. Maria Nuova (Reggio Emilia) and of the Unit of Dermatology

103 &Plastic Surgery, Campus Biomedico University (Rome).

104 The probands with mesothelioma were collected from the databases of Mesothelioma Biobank

105 (Alessandria), Molecular Genetics and Biology Unit, Santa Croce and Carle Hospital (Cuneo),

106 Thoracic Surgery Unit, AOU Maggiore della Carità (Novara) and Pathology Unit, Sapienza

107 University (Rome).

108 Selection criteria for melanoma patients were the following: diagnosis of melanoma with family

109 history for tumors associated with *BAP1* mutations (i.e. uveal melanoma, mesothelioma, renal cell

110 carcinoma) or juvenile melanoma with family history for melanoma or multiple melanomas with

111 family history for melanoma. Mesothelioma selection criteria were: familial mesothelioma or

112 mesothelioma with family history for *BAP1* associated tumors or melanoma and mesothelioma in

113 the same proband or mesothelioma and other tumors occurring in the same subject.

114 Overall, we identified 40 Italian families classified into three groups (Table I): 6 families with both

115 mesothelioma and melanoma, 23 families with melanoma (without mesothelioma) and with

116 familiarity for *BAP1* associated tumors and 11 families with mesothelioma (without melanoma) and

117 with familiarity for *BAP1* associated tumors. Details on proband's tumors with age at diagnosis and

118 family history are reported in Table I. Pedigrees are shown in Figure 1 (A1,B1,C1) and

119 Supplementary Figure 1 B1. Histological details, asbestos exposure, Fitzpatrick skin phototype and

120 other clinical information are described in Supplementary Table I.

121 All the probands were Caucasian of Italian ancestry and signed an informed consent to participate

122 in the research project.

123

124 *2.2 Histological diagnosis*

125 The diagnosis of melanoma was based on histological and immunochemistry findings.

126 Histological criteria were related to the evaluation of morphological and cytological features;

127 antibodies against Human Melanoma Black-45 (HMB-45), S100 protein and p16 were used in

128 equivocal cases. Melanomas were classified in subtypes, and staged on the basis of the American

129 Joint Committee on Cancer (AJCC) TNM classification (7th edition) [30].

130 The diagnosis of mesothelioma was based on standard histological and

131 immunohistochemical criteria, including positivity to calretinin, vimentin, cytokeratins 5 and 6, and

132 WT1 and negativity to carcinoembryonic antigen, thyroid transcription factor 1 and Ber-EP4. The

4

133 MMs were classified on the basis of the WHO classification of pleural tumors [31].

134

135 *2.3 Information on asbestos exposure of mesothelioma patients*

136 Since asbestos exposure is the main risk factor for MM [32], it was carefully evaluated in all

137 MM probands. Information on asbestos exposure at work, at home and in the general environment

138 for index cases included in the Malignant Mesothelioma Registry of the Piedmont Region (RMM)

139 was collected by RMM using a standardized questionnaire [33], that was administered by trained

140 interviewers. For familial cases identified in the proband's pedigree, information was gathered from

141 their attending clinician's reports, clinical records and data included in the RMM. Information was

142 collected during the personal interview of the proband if available. Asbestos exposure was

143 classified as: high exposure, low exposure, no exposure, unknown exposure. Details are reported in

144 Betti et al. 2015 [26].

145

146 *2.4 Information on risk factors of melanoma probands*

147 The role of UV exposure is well known in the development of melanoma. People with pale

148 skin are at higher risk for this tumor. Dysplastic and/or melanocytic nevi are considered

149 premalignant lesions in melanoma carcinogenesis [34]. Thus, the professional or chronic UV

150 exposure, the occurrence of dysplastic and/or melanocytic nevi and Fitzpatrick skin phototype were

151 evaluated in melanoma probands.

152

153 *2.5 DNA extraction and Sequencing analyses*

154 Blood samples were collected in vacutainers with ethylenediaminetetraacetic acid (EDTA)

155 and stored at -20°C until use. Genomic DNA was extracted from peripheral blood using QIAamp®

156 DNA Blood Maxi Kit (QIAGEN, Valencia, CA, USA), according to the manufacturer's protocol.

157 The 17 exons, intron-exon boundaries and promoter region (~1000bp upstream of the ATG)

158 of*BAP1* (NM_004656.2), the exons and intron-exon boundaries of *CDKN2A* (NM_000077.4), the

159 exon 2 of *CDK4* (NM_000075.3), the promoter of *TERT* (NM_198253.2), the missense variant

160 p.Glu318Lys of *MITF* (NM_000248.3) and the exon 10 of *POT1* (NM_015450) were amplified.

161 The primers were designed using the reference sequences provided by NCBI or Ensembl databases

162 (Supplementary Table II).

5

163   PCR reactions were performed in a 25 μL volume using GoTaq® Flexi Polymerase

164   (PROMEGA, Madison, WI, USA) for *BAP1* fragments amplification and Taq Gold 360+GC

165   enhancer for fragments amplification of melanoma predisposition genes. Sanger sequencing was

166   done using ABI PRISM 3130xl Genetic Analyzer or by IGA Technology Services (Udine, Italy).

167   Sequences were read by aligning with the reference sequence, using the GENESTREAM II Align

168   tool.

169   Each variant was confirmed on DNA obtained from a second independent blood vial.

170   Segregation analysis of three variants was done on DNA extracted from blood samples or tumor

171   FFPE of key relatives.

172

173   *2.6 Loss-of-heterozygosity analysis*

174   To assess *loss-of-heterozygosity (LOH)*, we performed Sanger sequencing and microsatellite

175   analysis on DNA obtained from tumor portions of FFPE (Formalin-fixed paraffin-embedded)

176   biopsy specimens. For each sample three serial 10μm thick sections were cut using microtome. The

177   slides were heated at 60°C for 30 min. The paraffin-embedded tissues were processed with xylene

178   and absolute ethanol. Deparaffinized tissues were scraped from the slides and placed in 1.5 ml-

179   Eppendorf tubes. DNA was purified using QIAamp® DNA FFPE Tissue Kit (QIAGEN, Valencia,

180   CA, USA) according to the manufacturer's protocol.

181   Sanger sequencing of the mutated region was then performed.LOH was indicated by loss of the

182   wild type allele in the mutation site.

183   Microsatellite analysis was performed using three markers (D3S3026, D3S3561 and D3S1578)

184   flanking the *BAP1* gene [20]. The analysis was carried out on genomic and tumor DNAs. Amplified

185   PCR products were separated with ABI 3130xl Genetic Analyzer and fragments were analyzed

186   using GeneMapper. LOH was indicated by apparent homozygosity at the microsatellite sites.

187

188   *2.7 Immunohistochemistry analysis*

189   To ascertain the role of germline *BAP1* or *CDKN2A* mutations, protein expression was evaluated

190   by immunohistochemistry (IHC) using a standard automated immunostainer (BenchMark,

191   Ventana Medical System, Tucson AZ).

192   Specific primary antibody against the anti-human BAP1 (mouse monoclonal, clone C-4, Santa

193   Cruz Biotechnology, Inc., Santa Cruz, CA) and anti-p16[INK4a] (mouse monoclonal, CLONE E6H4,

194   Ventana Medical System, Tucson, AZ) were used, respectively.

6

195 BAP1 was considered positive when a weak-to-strong nuclear positivity was shown. The specificity

196 of BAP1 stain was validated in serial negative control sections by omitting the primary antibody for

197 each immunohistochemical run. Non-neoplastic cells, such as vascular endothelium or

198 inflammatory cells, were considered as internal positive controls.

199 To detect the p16 protein, every tumor was given a score according to the intensity of the nuclear or

200 cytoplasmic staining (no staining; weak staining; moderate staining; strong staining). A stained

201 slide with a high-degree intraepithelial lesion of the uterine cervix was used as a positive control.

202

203   *2.8 In silico prediction analyses*

204   Pathogenicity assessment of missense variants is an important problem in cancer

205 predisposition syndrome [35].

206 To address the problem concerning *BAP1* missense variants, we have considered the following

207 parameters: results of LOH assay, results of IHC, frequency in 1000 Genomes Project and ExAC

208 databases, disease-causing potential using seven different prediction tools (Mutation taster, SIFT,

209 Provean, Polyphen-2, Mutation assessor, Condel, Phyre2), segregation analysis.

210 Since a change in a coding sequence may activate a cryptic splice site, we have also evaluated

211 splice site prediction using seven different tools (Human Splicing Finder, MaxEnt, BDGP,

212 NetGene2, GeneScan, FGENESH 2.6, FSPLICE 1.0).

213 As controls for the prediction programs, we used the five most frequent missense variants in ExAC,

214 (these variants are expected to be silent changes, since they are commonly found in normal

215 individuals).

216 We considered LOH, IHC or splice site prediction as the most important parameters. If LOH and

217 IHC data were not available, we considered as pathogenic a missense variant that has a disease

218 causing potential for at least 5/7 tools.

219 Segregation should be evaluated taking into consideration that frequent cancers may also occur as

220 phenocopies, i.e. patient with cancer but without the mutation identified in other affected family

221 members. Phenocopies are events not so rare in inherited cancer predisposition syndromes.

222

223   *2.9 Multiplex Ligation-dependent Probe Amplification (MLPA)*

224   MLPA was used to evaluate the presence of copy number variations. MLPA assays were

225 performed on 100-200ng of genomic DNAs using the SALSA MLPA P417 BAP1 probemix and

226 the SALSA MLPA probemix P419-A1 CDKN2A/2B-CDK4 Melanoma according to instructions

7

227 provided by the manufacturer (MRC-Holland, Amsterdam, The Netherlands). Amplified PCR
228 products were separated with ABI 3130xl Genetic Analyzer and fragments were analyzed using
229 Coffalyser.NET software (MRC-Holland).
230

231 **3. Results**

232 *3.1 Risk factors*

233 Information on asbestos exposure was available for 10 out of 12 mesothelioma probands
234 (Supplementary Table I). All of them showed asbestos exposure, in agreement with literature [32].
235 Possible occupational exposure was reported for four probands, para-occupational or household
236 exposure forfive patients and both possible occupational and household exposure for one proband.

237 One out of 28 melanoma probands showed professional or chronic UV exposure.
238 Information regarding Fitzpatrick skin phototype was available for 16 out of 28 probands: one had
239 phototype I, 10 had phototype II and 5 had phototype III. Information about dysplastic and/or
240 melanocytic nevi was available for 13 patients. Whereas one proband showed dysplastic nevi, 13
241 showed melanocytic nevi (7 probands <10, 2 probands 10-50, 4 probands >50). In total, 17 out of
242 28 probands showed at least well-documented risk factor (Supplementary Table I). Even if
243 information is lacking for 11 probands, our data confirms the high occurrence of well-documented
244 risk factors in melanoma patients [34].
245

246 *3.2 Mutation analysis*

247 Among the 40 probands with a family history of cancer we identified four *BAP1* germline
248 variants and a recurrent pathogenic germline mutation in *CDKN2A* in three and one index cases,
249 respectively (Table I).

250 Two *BAP1* and one *CDKN2A* germline variants were found in families with both
251 mesothelioma and melanoma. Two other *BAP1* germline variants were identified in a patient with
252 multiple cutaneous amelanotic melanomas (Table I).

253 The proband of family ID5 carried a heterozygous nonsense mutation in *BAP1* gene
254 (c.1153C>T, p.Arg385*, exon 12) (II-4 PB, Figure 1 A2). The mutation seemed heterozygous also
255 in the tumor samples (II-4 CM, II-4 MM, Figure 1 A2) and microsatellite analysis did not reveal
256 evidence of LOH (data not shown). However, IHC did not reveal any BAP1 nuclear expression in
257 both melanoma and mesothelioma cells (II-4 CM, II-4 MM, Figure 1A3). It is thus possible that the
258 second inactivating "hit" was either a somatic point mutation or a methylation event. This mutation

8

has been previously reported in three families with Spitz tumors and ocular and cutaneous melanoma [8,14], but this is the first report in association with MM. The proband developed two independent cutaneous melanomas (53, 57yrs), a meningioma (37yrs) and an epithelioid pleural mesothelioma (53yrs) (Figure 1 A1, Table I). The mutation was transmitted to the proband's healthy daughter (III-2 PB, Figure 1 A2) while the proband's brother died because of a basal cell carcinoma, but no sample was available for segregation analysis.

The proband of melanoma family ID16 developed two cutaneous amelanotic melanomas and showed a *BAP1* missense variant (c.1700A>C, p.Asp567Ala, exon 13) (IV-1 PB, Figure 1 B2) and a 5bp duplication in the promoter region (c.-594dupCCCGT) (IV-1 PB, Supplementary Figure 1 A1). Sequencing analysis of both parents confirmed that these variants were inherited *in cis* from the mother (III-5 PB, Figure 1 B2 and Supplementary Figure 1 A1), who presented with a non-Hodgkin cutaneous lymphoma. A healthy maternal aunt and a proband's healthy sister were also carriers (III-6 PB, IV-2 PB respectively, Figure 1 B2 and Supplementary Figure 1 A1). On the other hand, the proband's healthy father and the paternal uncle affected by cutaneous melanoma did not carry the variant allele. Thus, the cutaneous pigmented melanoma presented by the proband's paternal uncle was not due to the aforementioned *BAP1* germline variants.

The missense variant appeared in heterozygous state also in the two melanomas from the proband (IV-1 CM_1, IV-1 CM_2, Figure 1 B2).

Microsatellites analysis, performed on genomic and tumor DNAs, showed a decreased amount of the shorter paternal allele for the only informative marker (D3S3026) (IV-1 CM_1, IV-1 CM_2, Figure 1 B3).Considering a stromal cell contamination of tumor DNA from melanoma samples (determined as 64% in average, 15-90%) [36], this result suggests the loss of the wild type allele (LOH).

The presence of BAP1 protein was ascertained by IHC on FFPE pertaining to the two different melanomas from the proband (IV-1 CM_1, IV-1 CM_2, Figure 1 B4). BAP1 was normally expressed in the nucleus, showing that both the promoter duplication and the missense variant do not drastically affect protein levels. Since IHC is not quantitative, this result does not conflict with a tumor genotype that includes an expressed allele with a missense variant and a somatic deletion that abolishes the expression of the wild type protein.

To assess the pathogenicity of this missense variant, we have comparedthe p.Asp567Ala with all the eleven *BAP1* missense variants reported so far in patients with familiarity for *BAP1*

associated tumors (Supplementary Table III) using the parameters reported in the Materials and Methods section.

Using these parameters, 7/12 variants could be considered as disease causing. Two of them are predicted to cause aberrant splicing. One of these was experimentally confirmed [21], the second was not tested by the authors [6]. The other missense variants should be considered as *variant of unknown significance* (VUS), including p.Asp567Ala.

We have also performed a prediction of the three dimensional structure of the variant protein according to Protein Homology/analogy Recognition Engine v.2 (Phyre2). The mutant hydrophobic Ala567 is predicted to be buried within the globular portion of the protein and the relevant domains of the BAP1 protein seem to assume a different position (Supplementary Figure 2).

In conclusion, a functional assay is strongly needed to assess the pathogenicity of missense variants including p.Asp567Ala.

The duplication in the promoter was predicted to remove a MAZ (MYC-Associated Zinc Finger Protein) binding site by PROMO (TRANSFAC), but has no effect on transcription factor binding by AliBaba 2.1. The duplication is not reported in public databases (NCBI dbSNPs, 1000 Genomes Project phase 3, Exome Variant Server, Exome Aggregation Consortium at march 2015). Thus, considering that the protein is expressed, our data overall suggest that the duplication is a likely neutral variant.

The proband of family ID4 showed a heterozygote 19bp duplication (c.-247dupCCTTCGCCCCCGTCCCTCC) in the *BAP1* promoter region (II-1 PB, Supplementary Figure 1 B2) not reported in the above mentioned databases. This variant is predicted to generate an ETF binding site by AliBaba 2.1, but has no effect on transcription factor binding site by PROMO (TRANSFAC). IHC performed on the mesothelioma tissue showed nuclear expression of BAP1 protein (data not shown), supporting the hypothesis that this variant does not significantly alter gene transcription and could be considered as VUS. This family included both melanoma and MM in its tumor spectrum, but additional specimens were not available for further studies.

Probands from the other families were analyzed using the same strategy, but no other germline variant was found in *BAP1* gene.

Conversely, a recurrent pathogenic germline mutation (c.301G>T, p.Gly101Trp, exon 2) in *CDKN2A* was found in the family ID3 showing both melanoma and mesothelioma. The *CDKN2A* germline mutation was carried by the proband affected by cutaneous melanoma and by her mother affected by both cutaneous melanoma and mesothelioma (III-3 PB, II-3 FFPE non-tumor tissue

10

322 respectively, Figure 1 C2). This mutation was found in heterozygosity with the wild type sequence

323 also in mesothelioma from the proband's mother (II-3 MM, Figure 1 C2).

324 Mesothelioma cells showed nuclear staining at IHC with anti-p16 antibody (II-3 MM, Figure 1 C3)

325 although the intensity of nuclear expression was slightly lower in less differentiated tumor cells.

326 MLPA analysis was performed on germline DNA from all the probands, but no copy

327 number variations has been identified.

328 The probands from the other families under study were sequenced for the most common

329 melanoma predisposition genes (*CDKN2A, CDK4* exon 2*, TERT* promoter*, MITF* exon 9*, POT1*

330 exon 10*)*, but no additional germline variant was found. Details of the results for each proband are

331 reported in Table 1.

332

333 **4. Discussion**

334 Malignant mesothelioma is a rare and aggressive tumor that mainly arise from the pleura

335 and the peritoneum. The main risk factor is asbestos exposure [32]. Over 80% of MM patients have

336 a history of asbestos exposure, but only 10-17% of individuals heavily exposed to asbestos develop

337 MM [37]. Moreover, several families with multiples cases of MM have been described [38-41].

338 These observations suggest the involvement of inherited factors in the pathogenesis of MM. A

339 single high penetrance MM predisposition gene, *BAP1*, has been so far reported in familial cases of

340 MM [1]. Previous observations from our group and other researchers [26,42-43] limit the role of the

341 *BAP1* predisposition to the familial cases, as the mutation detection rate among sporadic cases

342 showing the mutations is less than 2% [26].

343 Cutaneous melanoma (CM) and uveal melanoma (UM) are also aggressive tumors that

344 originate from melanocytes of the skin and the eye, respectively. CM is responsible for 75% of

345 deaths from skin cancer [34] whereas UM accounts for less than 4% of all melanoma cases [44].

346 Although UV radiations are awell known environmental risk factor, 10% of melanomas are familial

347 regardless sun exposure or skin phototype. A subset of families (50%) carries mutations in one of

348 the known high penetrance melanoma predisposition genes: *CDKN2A, CDK4, POT1, TERT*, *MITF*

349 and *BAP1* [45].

350 Thus, germline mutations in *BAP1* are thought to be responsible for both MM and familial

351 melanoma. Within the 67 families identified so far as affected by this syndrome, 18 showed both

352 melanoma and mesothelioma [5-6,15-18]. Interestingly, six families from our series included

353 patients with mesothelioma and melanoma.

354   To better characterize the *BAP1* cancer syndrome we sequenced *BAP1* in 40 Italian families
355   in which multiple cases of either MM or melanoma, or cases of both malignancies occurred.
356   Moreover, we reasoned that given the shared predisposition for these tumors due to *BAP1*, other
357   genes predisposing to melanoma could also predispose to MM. Thus, we also analysed *CDKN2A,*
358   *CDK4, TERT, MITF* and *POT1* in the MM families.

359   We identified a germline *BAP1* truncating mutation (c.1153C>T, p.Arg385*) in a patient
360   who developed both MM and melanoma (Family ID5). This nonsense mutation has been previously
361   identified in three families with familial melanoma [8,14], but never in MM. This patient is still
362   alive five years after the diagnosis of epithelioid MM and was not heavily exposed to asbestos.
363   Epithelioid histology, long survival and low asbestos exposure have all been described in patients
364   with MM carrying germline *BAP1* mutations [1,46-48]. Further studies are needed to ascertain
365   whether these aspects are typical of the *BAP1* cancer syndrome. However, it is possible that studies
366   on familial predispositions are biased towards an over representation of long-survivors while short
367   survival might hamper sample collection and proper investigation.

368   A further patient (Family ID4), whose father died of MM, developed cutaneous melanoma
369   and breast cancer and carried a germline 19bp duplication in *BAP1* promoter region (c.-247dup
370   CCTTCGCCCCCGTCCCTCC). This VUS is not included in public databases, but could not be
371   traced in segregation analysis because key relatives were not available.

372   Our study also stresses the need of a reliable functional assay to evaluate the pathogenicity
373   of missense variants. In fact, the use of multiple *in silico* prediction tools did not allow to assess the
374   pathogenicity of the p.Asp567Ala variant found in a patient with multiple melanomas (family
375   ID16).

376   Finally, looking for mutations in the familial melanoma genes we found a germline
377   *CDKN2A* mutation in family ID3 (c.301G>T, p.Gly101Trp). This mutation has been frequently
378   identified in familial melanoma (44%) [49]. The proband was diagnosed with cutaneous melanoma,
379   whereas her mother had both cutaneous melanoma and MM. Mesothelioma tissue of the proband's
380   mother showed p16 nuclear expression. A retained p16 expression for this mutation is reported in
381   literature for melanoma [50]. Ghiorzo et al., reported that 28 out of 30 Gly101Trp-positive
382   melanoma samples retained p16 expression and in 25 of these, p16 expression was predominantly
383   nuclear.

12

384   Asbestos exposure at work of the proband's mother was assessed as 'low exposure', a

385   category including all occupational exposures occurring outside industries were asbestos was

386   directly used as a raw material.

387   Patients with *BAP1* mutations seem to develop mesothelioma even after a low asbestos

388   exposure [1]. Our finding suggests that the *CDKN2A* p.Gly101Trp behaves as *BAP1* mutations: the

389   mutation carrier is at high risk for tumors and the type of carcinogen exposure is important for the

390   cancer type that is developed. In conclusion, our study suggests for the first time that also *CDKN2A*

391   may predispose to MM.

392   Although the coincidence of two rare tumors in a single patient promptly suggests a

393   common origin, we cannot exclude the independent occurrence of a malignant mesothelioma in a

394   patient otherwise predisposed to melanoma. Indeed, we failed to identify additional *CDKN2A*

395   germline mutations in our series but the same is true for *BAP1* whose mutations are very rare and do

396   not explain most familial clustering of tumors investigated in this work, as well as cases or families

397   with both melanoma and renal cell cancer.

398   Both *BAP1* and *CDKN2A* genes are found somatically deleted or mutated in MM tissues

399   [51]. This study further supports that loss of either BAP1 or CDKN2A is an important step in both

400   melanoma and MM carcinogenesis and individuals that carry a germline mutation in either of these

401   two genes might have an increased risk for both tumors.

402   Three other families (IDs 1,2,6) showed co-occurrence of MM and melanoma. The fact that

403   none of these families showed germline mutations in either *BAP1* or *CDKN2A*, *CDK4*, *TERT*, *MITF*

404   and *POT1* suggests that other genes may be involved in melanoma and MM shared predisposition.

405   Other cancer predisposition syndromes have been reportedly associated with both tumors. Patients

406   with Li Fraumeni syndrome due to *TP53*mutations frequently develop melanoma [52-53], more

407   rarely MM [54]. Moreover, the occurrence of both melanoma and mesothelioma has been reported

408   in a patient with neurofibromatosis type 2, due to heterozygous germline mutations in *NF2* [55-57].

409   Both *TP53* and *NF2* are often somatically deleted in MM. Thus, at least four genes that cause

410   inherited cancer predisposition syndromes, including MM and melanoma in their spectrum, are

411   often subjected to inactivating somatic mutations or deletions both in melanoma and MM [7,58-59].

412   An occurrence of MM as a second tumor after melanoma was reported two-fold more frequently

413   than expected (p<0.05, in males) in a recent survey performed on Italian cancer registries [60]. A

414   genetic susceptibility may explain the statistically significant co-occurrence of the two tumors in the

415   same individual.

13

A common denominator between mesothelioma and melanoma is also the well-defined role of environmental carcinogens. In mice, germline *Bap1* mutations increase the susceptibility to asbestos-induced mesothelioma formation [61] and *BAP1* mutation carriers may be prone to UV carcinogenesis and melanoma development [5].

Our study suggests that *CDKN2A*, in addition to *BAP1*, could be involved in melanoma and mesothelioma susceptibility and these tumors share key steps that drive carcinogenesis and may cause familial aggregations of cases. Our hypothesis should be confirmed on a larger patients serie. Our study also suggests that other unknown genes may be involved in familial MM or familial melanoma, including uveal melanoma. Exome-sequencing analysis in families that show both MM and melanoma could help to identify new genes involved in the shared susceptibility between these tumors.

References
[1] Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, Cox NJ, Dogan AU, Pass HI, Trusa S, Hesdorffer M, Nasu M, Powers A, Rivera Z, Comertpay S, Tanji M, Gaudino G, Yang H, Carbone M. 2011. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 43(10):1022-5. doi: 10.1038/ng.912.
[2] Wiesner T, Fried I, Ulz P, Stacher E, Popper H, Murali R, Kutzner H, Lax S, Smolle-Juttner F, Geigl JB, Speicher MR. 2012. Toward an improved definition of the tumor spectrum associated with BAP1 germline mutations. J Clin Oncol 30(32):e337-40. doi: 10.1200/JCO.2011.41.2965.
[3] Ribeiro C, Campelos S, Moura CS, Machado JC, Justino A, Parente B. 2013. Well-differentiated papillary mesothelioma: clustering in a Portuguese family with a germline BAP1 mutation. Ann Oncol 24:2147-50. doi: 10.1093/annonc/mdt135.
[4] Cheung M, Talarchek J, Schindeler K, Saraiva E, Penney LS, Ludman M, Testa JR. 2013.Further evidence for germline BAP1 mutations predisposing to melanoma and malignant mesothelioma. Cancer Genet 206:206-10. doi: 10.1016/j.cancergen.2013.05.018.
[5] Cheung M, Kadariya Y, Talarchek J, Pei J, Ohar JA, Kayaleh OR, Testa JR. 2015. Germline BAP1 mutation in a family with high incidence of multiple primary cancers and a potential gene-environment interaction. Cancer Lett369(2):261-5. doi: 10.1016/j.canlet.2015.09.011.
[6] Ohar JA, Cheung M, Talarchek J, Howard SE, Howard TD, Hesdorffer M, Peng H, Rauscher FJ, Testa JR. 2016. Germline BAP1 Mutational Landscape of Asbestos-Exposed Malignant Mesothelioma Patients with Family History of Cancer. Cancer Res 76(2):206-15. doi: 10.1158/0008-5472.CAN-15-0295.
[7] Wiesner T, Obenauf AC, Murali R, Fried I, Griewank KG, Ulz P, Windpassinger C, Wackernagel W, Loy S, Wolf I, Viale A, Lash AE, Pirun M, Socci ND, Rütten A, Palmedo G, Abramson D, Offit K, Ott A, Becker JC, Cerroni L, Kutzner H, Bastian BC, Speicher MR. 2011. Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet 43(10):1018-21. doi: 10.1038/ng.910.
[8] Njauw CN, Kim I, Piris A, Gabree M, Taylor M, Lane AM, DeAngelis MM, Gragoudas E, Duncan LM, Tsao H. 2012.Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families. PLoS One 7:e35295.doi: 10.1371/journal.pone.0035295.
[9] Aoude LG, Wadt K, Bojesen A, Crüger D, Borg A, Trent JM, Brown KM, Gerdes AM, Jönsson G, Hayward NK.

14

2013. A BAP1 Mutation in a Danish Family Predisposes to Uveal Melanoma and Other Cancers. PloS One 8:e72144. doi: 10.1371/journal.pone.0072144.

[10] Hoiom V, Edsgard D, Helgadottir H, Eriksson H, All-Ericsson C, Tuominen R, Ivanova I, Lundeberg J, Emanuelsson O, Hansson J. 2013. Hereditary uveal melanoma: A report of a germline mutation in BAP1. Genes Chromosomes Cancer 52(4):378-84. doi: 10.1002/gcc.22035.

[11] Maerker DA, Zeschnigk M, Nelles J, Lohmann DR, Worm K, Bosserhoff AK, Krupar R, Jägle H. 2014. BAP1 germline mutation in two first grade family members with uveal melanoma. Br J Ophthalmol 98:224-227. doi: 10.1136/bjophthalmol-2013-303814.

[12] Pilarski R, Cebulla CM, Massengill JB, Rai K, Rich T, Strong L, McGillivray B, Asrat MJ, Davidorf FH, Abdel-Rahman MH. 2014. Expanding the clinical phenotype of hereditary BAP1 cancer predisposition syndrome, reporting three new cases. Genes Chromosomes Cancer 53(2):177-82. doi: 10.1002/gcc.22129.

[13] Cebulla CM, Binkley EM, Pilarski R, Massengill JB, Rai K, Liebner DA, Marino MJ, Singh AD, Abdel-Rahman MH. 2015. Analysis of BAP1 Germline Gene Mutation in Young Uveal Melanoma Patients. Ophthalmic Genet 36(2):126-31. doi: 10.3109/13816810.2015.1010734.

[14] Gupta MP, Lane AM, DeAngelis MM, Mayne K, Crabtree M, Gragoudas ES, Kim IK. 2015. Clinical Characteristics of Uveal Melanoma in Patients With Germline BAP1 Mutations. JAMA Ophthalmol 133(8):881-7. doi: 10.1001/jamaophthalmol.2015.1119.

[15] Gerami P, Yélamos O, Lee CY, Obregon R, Yazdan P, Sholl LM, Guitart GE, Njauw CN, Tsao H. 2015. Multiple Cutaneous Melanomas and Clinically Atypical Moles in a Patient With a Novel Germline BAP1 Mutation. JAMA Dermatol 151(11):1235-9. doi: 10.1001/jamadermatol.2015.1701.

[16] Rai K, Pilarski R, Cebulla CM, Abdel-Rahman MH. 2016. Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases.Clin Genet 89(3):285-94. doi: 10.1111/cge.12630.

[17] Klebe S, Driml J, Nasu M, Pastorino S, Zangiabadi A, Henderson D, Carbone M. 2015. BAP1 hereditary cancer predisposition syndrome: a case report and review of literature. Biomark Res 3:14.doi: 10.1186/s40364-015-0040-5.

[18] McDonnell KJ, Gallanis GT, Heller KA, Melas M, Idos GE, Culver JO, Martin SE, Peng DH, Gruber SB. 2016. A novel BAP1 mutation is associated with melanocytic neoplasms and thyroid cancer. Cancer Genet 209(3):75-81.doi: 10.1016/j.cancergen.2015.12.007.

[19] Busam KJ, Wanna M, Wiesner T. Multiple epithelioid Spitz nevi or tumors with loss of BAP1 expression: a clue to a hereditary tumor syndrome. JAMA Dermatol. 2013 Mar;149(3):335-9. doi: 10.1001/jamadermatol.2013.1529.

[20] Abdel-Rahman MH, Pilarski R, Cebulla CM, Massengill JB, Christopher BN, Boru G, Hovland P, Davidorf FH. 2011. Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J Med Genet 48(12):856-9. doi: 10.1136/jmedgenet-2011-100156.

[21] Wadt K, Choi J, Chung JY, Kiilgaard J, Heegaard S, Drzewiecki KT, Trent JM, Hewitt SM, Hayward NK, Gerdes AM, Brown KM. 2012. A cryptic BAP1 splice mutation in a family with uveal and cutaneous melanoma, and paraganglioma. Pigment Cell Melanoma Res 25(6):815-8.

[22] Popova T, Hebert L, Jacquemin V, Gad S, Caux-Moncoutier V, Dubois-d'Enghien C, Richaudeau B, Renaudin X, Sellers J, Nicolas A, Sastre-Garau X, Desjardins L, Gyapay G, Raynal V, Sinilnikova OM, Andrieu N, Manié E, de Pauw A, Gesta P, Bonadona V, Maugard CM, Penet C, Avril MF, Barillot E, Cabaret O, Delattre O, Richard S, Caron O, Benfodda M, Hu HH, Soufir N, Bressac-de Pailleretes B, Stoppa-Lyonnet D, Stern MH. 2013. Germline BAP1 Mutations Predispose to Renal Cell Carcinomas. Am J Hum Genet 92:974-980. doi: 10.1016/j.ajhg.2013.04.012.

[23] Farley MN, Schmidt LS, Mester JL, Peña-Llopis S, Pavia-Jimenez A, Christie A, Vocke CD, Ricketts CJ, Peterson J, Middelton L, Kinch L, Grishin N, Merino MJ, Metwalli AR, Xing C, Xie XJ, Dahia PL, Eng C, Linehan WM, Brugarolas J. 2013. A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma. Mol Cancer Res 11(9):1061-71. doi: 10.1158/1541-7786.MCR-13-0111.

[24] Wadt KA, Aoude LG, Johansson P, Solinas A, Pritchard A, Crainic O, Andersen MT, Kiilgaard JF, Heegaard S, Sunde L, Federspiel B, Madore J, Thompson JF, McCarthy SW, Goodwin A, Tsao H, Jönsson G, Busam K, Gupta R, Trent JM, Gerdes AM, Brown KM, Scolyer RA, Hayward NK. 2015. A recurrent germline BAP1 mutation and extension of the BAP1 tumor predisposition spectrum to include basal cell carcinoma. Clin Genet 88(3):267-72. doi: 10.1111/cge.12501.

[25] de la Fouchardière A, Cabaret O, Savin L, Combemale P, Schvartz H, Penet C, Bonadona V, Soufir N, Bressac-de Pailleretes B. 2015. Germline BAP1 mutations predispose also to multiple basal cell carcinomas. Clin Genet 88(3):273-7. doi: 10.1111/cge.12472.

[26] Betti M, Casalone E, Ferrante D, Romanelli A, Grosso F, Guarrera S, Righi L, Vatrano S, Pelosi G, Libener R, Mirabelli D, Boldorini R, Casadio C, Papotti M, Matullo G, Magnani C, Dianzani I. 2015. Inference on germline BAP1 mutations and asbestos exposure from the analysis of familial and sporadic mesothelioma in a high-risk area. Genes Chromosomes Cancer 54(1):51-62. doi: 10.1002/gcc.22218.

15

[27] Moreno L, Linossi C, Esteban I, Gadea N, Carrasco E, Bonache S, Gutiérrez-Enríquez S, Cruz C, Díez O, Balmaña J. Germline BRCA testing is moving from cancer risk assessment to a predictive biomarker for targeting cancer therapeutics. Clin Transl Oncol. 2016 Jan 7.

[28] Hill VK, Gartner JJ, Samuels Y, Goldstein AM. 2013. The genetics of melanoma: recent advances. Annu Rev Genomics Hum Genet 14:257-79. doi: 10.1146/annurev-genom-091212-153429.

[29] Shi J, Yang XR, Ballew B, Rotunno M, Calista D, Fargnoli MC, Ghiorzo P, Bressac-de Paillerets B, Nagore E, Avril MF, Caporaso NE, McMaster ML, Cullen M, Wang Z, Zhang X; NCI DCEG Cancer Sequencing Working Group; NCI DCEG Cancer Genomics Research Laboratory; French Familial Melanoma Study Group, Bruno W5, Pastorino L, Queirolo P, Banuls-Roca J, Garcia-Casado Z, Vaysse A, Mohamdi H, Riazalhosseini Y, Foglio M, Jouenne F, Hua X, Hyland PL, Yin J, Vallabhaneni H, Chai W, Minghetti P, Pellegrini C, Ravichandran S, Eggermont A, Lathrop M, Peris K, Scarra GB, Landi G, Savage SA, Sampson JN, He J, Yeager M, Goldin LR, Demenais F, Chanock SJ, Tucker MA, Goldstein AM, Liu Y, Landi MT. 2014. Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma. Nat Genet 46(5):482-6. doi: 10.1038/ng.2941.

[30] Edge SB, Compton CC. 2010. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann SurgOncol 17(6):1471-4. doi: 10.1245/s10434-010-0985-4.

[31] Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. 2015. Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart.JThoracOncol 10(9):1240-2. doi: 10.1097/JTO.0000000000000663.

[32] Pinto C, Novello S, Torri V, Ardizzoni A, Betta PG, Bertazzi PA, Casalini GA, Fava C, Fubini B, Magnani C, Mirabelli D, Papotti M, Ricardi U, Rocco G, Pastorino U, Tassi G, Trodella L, Zompatori M, Scagliotti G. 2013. Second Italian consensus conference on malignant pleural mesothelioma: state of the art and recommendations.Cancer Treat Rev39(4):328-39. doi: 10.1016/j.ctrv.2012.11.004.

[33] Magnani C, Agudo A, González CA, Andrion A, Calleja A, Chellini E, Dalmasso P, Escolar A, Hernandez S, Ivaldi C, Mirabelli D, Ramirez J, Turuguet D, Usel M, Terracini B. 2000. Multicentric study on malignant pleural mesothelioma and non-occupational exposure to asbestos.British Journal of Cancer.83, 104–11.

[34] Potrony M, Badenas C, Aguilera P, Puig-Butille JA, Carrera C, Malvehy J, Puig S. 2015. Update in genetic susceptibility in melanoma. Ann Transl Med 3(15):210. Review. doi: 10.3978/j.issn.2305-5839.2015.08.11.

[35] Medeiros F, Lindor NM, Couch FJ, Highsmith WE Jr. The germline MLH1 K618A variant and susceptibility to Lynch syndrome-associated tumors.J MolDiagn. 2012 May-Jun; 14(3):264-73. doi:10.1016/j.jmoldx.2012.01.006.

[36] Shain AH, Yeh I, Kovalyshyn I, Sriharan A, Talevich E, Gagnon A, Dummer R, North J, Pincus L, Ruben B, Rickaby W, D'Arrigo C, Robson A, Bastian BC. 2015. The Genetic Evolution of Melanoma from Precursor Lesions. N Engl J Med 373(20):1926-36. doi: 10.1056/NEJMoa1502583.

[37] Hodgson JT, Darnton A. 2000. The Quantitative Risks of Mesothelioma and Lung Cancer in Relation to Asbestos Exposure.AnnOccupHyg 44:565–601.doi: 10.1136/oem.2009.052860.

[38] Ascoli V, Cavone D, Merler E, Barbieri PG, Romeo L, Nardi F, Musti M. 2007. Mesothelioma in blood related subjects: report of 11 clusters among 1954 Italy cases and review of the literature. Am J IndMed 50(5):357-69.

[39] Ascoli V, Romeo E, Carnovale Scalzo C, Cozzi I, Ancona L, Caraviani F, Balestri A, Gasperini L, Forastiere F. 2014. Familial malignant mesothelioma: a population-based study in Central Italy (1980-2012). Cancer Epidemiol 38:273-278.doi: 10.1016/j.canep.2014.02.014.

[40] Dogan AU, Baris YI, Dogan M, Emri S, Steele I, Elmishad AG, Carbone M. 2006. Genetic predisposition to fiber carcinogenesis causes a mesothelioma epidemic in Turkey. Cancer Res 66(10):5063-8.

[41] de Klerk N, Alfonso H, Olsen N, Reid A, Sleith J, Palmer L, Berry G, Musk AB. 2013. Familial aggregation of malignant mesothelioma in former workers and residents of Wittenoom, Western Australia. Int J Cancer132(6):1423-8. doi: 10.1002/ijc.27758.

[42] Rusch A, Ziltener G, Nackaerts K, Weder W, Stahel RA, Felley-Bosco E. 2015. Prevalence of BRCA-1 associatedprotein1germlinemutation in sporadic malignant pleural mesothelioma cases. Lung Cancer 87(1):77-9. doi:10.1016/j.lungcan.2014.10.017.

[43] Sneddon S, Leon JS, Dick IM, Cadby G, Olsen N, Brims F, Allcock RJ, Moses EK, Melton PE, de Klerk N, Musk AW, Robinson BW, Creaney J. Absence of germline mutations in BAP1 in sporadic cases of malignant mesothelioma.Gene. 2015 May25;563(1):103-5. doi: 10.1016/j.gene.2015.03.031.

[44] Jovanovic P, Mihajlovic M, Djordjevic-Jocic J, Vlajkovic S, Cekic S, Stefanovic V. 2013. Ocular melanoma: an overview of the current status. Int J Clin Exp Pathol 6(7):1230-44.

[45] Read J, Wadt KAW, Hayward NK. 2015. Melanoma genetics. J Med Genet 0:1-14. doi: 10.1136/jmedgenet-2015-103150.

[46] Arzt L, Quehenberger F, Halbwedl I, Mairinger T, Popper HH. 2014. BAP1 protein is a progression factor in malignant pleural mesothelioma. Pathol Oncol Res 20(1):145-51. doi: 10.1007/s12253-013-9677-2.

16

575 [47]Baumann F, Flores E, Napolitano A, Kanodia S, Taioli E, Pass H, Yang H, Carbone M. 2015. Mesothelioma
576 patients with germline BAP1 mutations have 7-fold improved long-term survival. Carcinogenesis 36(1):76-81. doi:
577 10.1093/carcin/bgu227.
578 [48] Yoshikawa Y, Sato A, Tsujimura T, Emi M, Morinaga T, Fukuoka K, Yamada S, Murakami A, Kondo N,
579 Matsumoto S, Okumura Y, Tanaka F, Hasegawa S, Nakano T, Hashimoto-Tamaoki T. 2012. Frequent inactivation of
580 the BAP1 gene in epithelioid-type malignant mesothelioma. Cancer Sci 103(5):868-74. doi: 10.1111/j.1349-
581 7006.2012.02223.x.
582 [49] Pedace L, De Simone P, Castori M, Sperduti I, Silipo V, Eibenschutz L, De Bernardo C, Buccini P, Moscarella E,
583 Panetta C, Ferrari A, Grammatico P, Catricalà C. 2011. Clinical features predicting identification of CDKN2A
584 mutations in Italian patients with familial cutaneous melanoma.Cancer Epidemiol 35(6):e116-20.
585 [50] Ghiorzo P, Villaggio B, Sementa AR, Hansson J, Platz A, Nicoló G, Spina B, Canepa M, Palmer JM, Hayward
586 NK, Bianchi-Scarrà G. 2004. Expression and localization of mutant p16 proteins in melanocytic lesions from familial
587 melanoma patients.Hum Pathol 35(1):25-33.
588 [51] Lo Iacono M, Monica V, Righi L, Grosso F, Libener R, Vatrano S, Bironzo P, Novello S, Musmeci L, Volante
589 M,Papotti M, Scagliotti GV. 2015. Targeted next-generation sequencing of cancer genes in advanced stage malignant
590 pleural mesothelioma: a retrospective study. J Thorac Oncol 10(3):492-9. doi: 10.1097/JTO.0000000000000436.
591 [52] Kollipara R, Cooley LD, Horii KA, Hetherington ML, LeBoit PE, Singh V, Zwick DL. 2014. Spitzoid Melanoma
592 in a Child with Li-Fraumeni Syndrome Pediatr Dev Pathol 17(1):64-69. doi: 10.2350/13-09-1380-CR.1.
593 [53] Curiel-Lewandrowski C, Speetzen LS, Cranmer L, Warneke JA, Loescher LJ. 2011. Multiple primary cutaneous
594 melanomas in Li-Fraumeni syndrome. Arch Dermatol 147(2):248-50. doi: 10.1001/archdermatol.2010.428.
595 [54] Ceelen WP, Van Dalen T, Van Bockstal M, Libbrecht L, Sijmons RH. 2011. Malignant peritoneal mesothelioma in
596 a patient with Li-Fraumenisyndrome. J Clin Oncol. 29(17):e503-5. doi: 10.1200/JCO.2010.34.1933.
597 [55] Bacin F, Kemeny JL, D'Hermies F, Rozan R, Decroix P, Dalens H, Kalifa C. 1993. Malignant melanoma of the
598 choroid associated with neurofibromatosis. J Fr Ophtalmol 16(3):184-90.
599 [56] Baser ME, Rai H, Wallace AJ, Evans DG. 2005. Neurofibromatosis 2 (NF2) and malignant mesothelioma in a man
600 with a constitutional NF2 missense mutation. Fam Cancer. 4(4):321-2.
601 [57] Shields JA, Shields CL, Lavrich J. 2002. Melanocytoma of optic disk in a patient with neurofibromatosis 2 Retina
602 22(2):222-3.
603 [58] Zauderer MG, Bott M, McMillan R, Sima CS, Rusch V, Krug LM, Ladanyi M. 2013. Clinical Characteristics of
604 Patients with Malignant Pleural Mesothelioma Harboring Somatic BAP1 Mutations. J ThoracOncol 8(11):1430-3. doi:
605 10.1097/JTO.0b013e31829e7ef9.
606 [59] Sekido Y. 2013. Molecular pathogenesis of malignant mesothelioma. Carcinogenesis 34(7):1413-9. doi:
607 10.1093/carcin/bgt166.
608 [60] AIRTUM Working Group. 2013. Italian cancer figures, report 2013: Multiple tumours. Epidemiol Prev 37(4-5
609 Suppl 1):1-152.
610 [61] Xu J, Kadariya Y, Cheung M, Pei J, Talarchek J, Sementino E, Tan Y, Menges CW, Cai KQ, Litwin S, Peng H,
611 Karar J, Rauscher FJ, Testa JR. 2014. Germline mutation of Bap1 accelerates development of asbestos-induced
612 malignant mesothelioma. Cancer Res 74(16):4388-97. doi: 10.1158/0008-5472.CAN-14-1328.
613

614 **URL**
615 http://www.ncbi nlm nih.gov/SNP/
616 http://www.1000genomes.org/1000-genomes-browsers
617 http:// evs.gs.washington.edu/EVS/
618 http://exac.broadistitute.org
619 http://www.ncbi nlm nih.gov/
620 http://www.ensembl.org
621 http://www.mutationtaster.org
622 http://sift.jcvi.org/www/SIFT_enst_submit html
623 http://provean.jcvi.org/seq_submit.php
624 http://genetics.bwh harvard.edu/pph2/
625 http://mutationassessor.org/v1
626 http://bg.upf.edu/fannsdb/
627 http://www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi?id=index
628 http://www.umd.be/HSF3/
629 http://genes.mit.edu/burgelab/maxent/Xmaxentscan_scoreseq_acc html
630 http://www.fruitfly.org/seq_tools/splice.html
631 http://www.cbs.dtu.dk/services/NetGene2/

632 http://genes.mit.edu/GENSCAN.html
633 http://www.softberry.com/berry.phtml?topic=fgenesh&group=help&subgroup=gfind
634 http://www.softberry.com/berry.phtml?topic=fsplice&group=help&subgroup=gfind
635
636
637
638
639
640

Figure 1 - Families with germline mutations

The probands for each family are denoted by a black arrow. A plus symbol indicates individuals who carry germline mutations, a minus symbol indicates wild type individuals. A grey arrow denotes the mutation in the electropherograms. PB (peripheral blood), CM (cutaneous melanoma), MM (mesothelioma), FFPE (formalin-fixed paraffin-embedded).

A. Family ID5. A1. Pedigree: the proband (II-4) had multiple cancers, her brother (II-1) had basal cell carcinoma of the skin and her mother (I-2) had gastric cancer. A2. Electropherograms: *BAP1* germline mutation (c.1153C>T p.Arg385*) was carried in PB and in both tumors of the proband (II-4 PB, II-4 CM, II-4 MM). The proband's healthy daughter (III-2 PB) also carries the mutation. Other family members were not available. A3. IHC: II-4 CM: cutaneous melanoma cells showed the expression of specific Melanoma Antigen (Melan A); the same cells showed the loss of BAP1 nuclear expression(thin arrow), while BAP1 nuclear staining was retained in normal cells of the surrounding skin (thick arrow) and infiltrating inflammatory cellsII-4 MM: epithelioid mesothelioma cells showed the expression of specific mesothelial antigen (Calretinin); the same cells showed the loss of BAP1 nuclear expression (thin arrows), while BAP1 nuclear staining was retained in the normal endothelial cells and infiltrating inflammatory cells (thick arrows).

B. Family ID16. B1. Pedigree: the proband (IV-1) had two cutaneous amelanotic melanomas, her mother (III-5) had non-Hodgkin cutaneous lymphoma and her paternal uncle (III-2) had cutaneous melanoma. B2. Electropherograms: a *BAP1* missense mutation (c.1700A>C p.Asp567Ala) was found in the proband (IV-1 PB), in a sister (IV-2 PB), in her mother (III-5 PB) and in her maternal aunt (III-6 PB). The mutation was heterozygous also in both cutaneous amelanotic melanomas of the proband (IV-1 CM_1, IV-1 CM_2). B3. Microsatellite marker (D3S3026): a decreased amount of paternal allele was shown in a specimen from the second melanoma developed by the proband (IV-1 T, grey arrow) as compared with genomic DNA. B4. IHC: BAP1 was normallyexpressed in the nucleus of both cutaneous amelanotic melanomas of the proband (IV-1 CM_1 and IV-1 CM_2).

C. Family ID3. C1. Pedigree: the proband (III-3) had cutaneous melanoma, the proband's mother (II-3) had cutaneous melanoma and mesothelioma. C2. Electropherograms: *CDKN2A* germline mutation (c.301G>T p.Gly101Trp) was detected in the proband (III-3 PB) and in the proband's mother (II-3 FFPE non-tumor tissue, II-3 MM). Melanoma specimen of II-3 wasnotavailable. C3. IHC: epithelioid mesothelioma from the proband's mother (II-3 MM) showed intranuclear positivity to anti p16 antibody in neoplastic cells (left panel). The intensity of nuclear expression was slightly lower in less differentiated tumor cells (right panel).

18

Figure 1

A Family ID5

A1

A2

BAP1 c.1153C>T

A3

Melan A_II-4 CM

BAP1_II-4 CM

Calretinin_II-4 MM

BAP1_II-4 MM

19

B Family ID16

B1

B2

BAP1 c.1700A>C

B3

D3S3026

B4

685

686

C Family ID3

C1

C2

III-3 PB

II-3 FFPE non-tumor tissue

II-3 MM

CDKN2A c.301G>T

C3

687
688
689

21

690 **Table I** – Concise clinical details and testing results of the 40 probands
691

Family ID (sex)	Proband's tumors (age at diagnosis)	Family history	BAP1	CDKN2A	CDK4 (ex2)	TERT (prom)	MITF (p.Glu318Lys)	POT1 (ex10)	Other genes
Probands/families with both mesothelioma and melanoma									
1 (F)	Cutaneous melanoma (33)	Biphasic mesothelioma (mother) Breast cancer (maternal grandmother)	wt	wt	wt	wt	wt	wt	
2 (F)	Nasopharynx carcinoma (24) Cutaneous melanoma (43) Rectal carcinoma (56)	Mesothelioma (father) other tumors in relatives of the paternal family	wt	wt	wt	wt	wt	wt	TP53 wt
3 (F)	Cutaneous melanoma (42)	Mesothelioma and cutaneous melanoma (mother)	wt	**c.301G>T p.Gly101Trp**	wt	nd	wt	nd	-
4 (F)	Cutaneous melanoma (30) Breastcancer (58)	Mesothelioma (father), breast cancer (mother), papillary renal cell carcinoma type 2 (brother)	**c.-247dupCCTTCGC CCCCGTCCCTCC**	wt	wt	wt	wt	nd	-
5 (F)	Meningioma (37) Cutaneous melanoma (53) Epithelioid pleura lmesothelioma (53) Cutaneous melanoma (57)	Gastric cancer (mother), basal cell carcinoma of the skin (brother)	**c.1153C>T p.Arg385***	wt	wt	wt	wt	wt	-
6 (M)	Epithelioid mesothelioma (65)	Melanoma (brother)	wt	wt	wt	wt	wt	nd	-
Probands/families with melanoma (without mesothelioma) and features of inherited cancer predisposition									
7 (F)	Bilateral uveal melanoma (25, 30) Breast cancer (*in situ*, 40)	Acustic neurinoma (sister), bladder (mother), head/neck tumors in both maternal and paternal families	wt	wt	wt	wt	wt	wt	BRCA1 BRCA2 wt
8 (M)	Iris-Uveal melanoma (31)	Negative	wt	wt	wt	wt	wt	wt	-
9 (F)	Uveal melanoma (67) Cutaneous melanoma (72)	Cutaneous melanoma (daughter, niece)	wt	wt	wt	wt	wt	nd	-
10 (F)	Choroidal melanoma (63) Bilateral breast cancer (60, 65)	Breast cancer (sister, maternal cousin, paternal aunt), renal cancer (maternal aunt)	wt	wt	wt	wt	wt	wt	TP53 BRCA1 BRCA2 wt
11 (F)	Cutaneous melanoma (46)	Ocular melanoma (uveal, father),	wt	wt	wt	wt	wt	wt	-

1

		colon cancer							
12 (F)	Renal cell cancer (41) Two synchronous cutaneous melanomas (43)	Negative	wt	wt	wt	wt	wt	wt	-
13 (M)	Lentigo maligna melanoma (65)	Cutaneous melanoma, renal cell cancer	wt	wt	wt	wt	wt	wt	-
14 (M)	Lentigo melanoma (54) Two synchronous cutaneous primary melanomas (58)	Cutaneous melanoma (mother), renal cell cancer + uterus cancer + breast cancer (sister), pancreatic carcinoma, liver cancer, prostate cancer	wt	wt	wt	wt	wt	wt	-
15 (F)	Two cutaneous primary melanomas (34, 40)	Cutaneous melanoma (paternal uncles), renal cell cancer (father), lung cancer (two paternal uncles)	wt	wt	wt	wt	wt	wt	-
16 (F)	Two cutaneous amelanotic melanomas (24, 25)	Cutaneous melanoma (paternal uncle), non-Hodgkin cutaneous lymphoma (low grade, CD20+, mother)	**c.1700A>C (p.Asp567Ala) c.-594dupCCCGT**	wt	wt	wt	wt	wt	**-**
17 (F)	Two cutaneous primary melanomas (31, 33)	Cutaneous melanoma (father)	wt	wt	wt	wt	wt	wt	-
18 (F)	Two cutaneous melanomas (56, 57)	Cutaneous melanoma (father)	wt	wt	wt	wt	wt	wt	-
19 (F)	Two synchronous cutaneous primary melanomas (67) Facial basal cell carcinoma (69)	Cutaneous melanoma (brother), breast cancer, CNS, prostate cancer	wt	wt	wt	wt	wt	wt	-
20 (M)	Cutaneous melanoma (20)	Cutaneous melanoma (mother), breast and colon cancer	wt	wt	wt	wt	wt	wt	-
21 (M)	Cutaneous melanoma (24)	Cutaneous melanoma (mother), prostate cancer, vulvar cancer	wt	wt	wt	wt	wt	wt	-
22 (F)	Cutaneous melanoma (*in situ*, 27)	Cutaneous melanoma (father), prostate cancer	wt	wt	wt	wt	wt	wt	-
23 (M)	Cutaneous melanoma (32)	Cutaneous melanoma (sister)	wt	wt	wt	wt	wt	wt	-
24 (F)	Cutaneous melanoma (35)	Cutaneous melanoma + thyroid cancer (father)	wt	wt	wt	wt	wt	wt	-
25 (F)	Cutaneous melanoma (39)	Cutaneous melanoma + colon cancer (brother)	wt	wt	wt	wt	wt	wt	-

# (Sex)	Proband diagnosis (age)	Family history							
26 (M)	Cutaneous melanoma (82)	Cutaneous melanoma (brother), pancreatic cancer (sister)	wt	wt	wt	wt	nd	nd	-
27 (M)	Testicular teratoma (27) Multinodular goiter Ten cutaneous primary melanomas (38 to 52)	Breast cancer (mother)	wt	p.Thr77Ala§	wt	wt	wt	wt	-
28 (M)	Lipoma (27) Adrenal cortex adenoma (53) Three cutaneous primary melanomas (57, 58)	Prostate cancer (father), liver cancer (paternal uncle and paternal grandfather)	wt	wt	wt	wt	wt	wt	-
29 (M)	Cutaneous melanoma (61)	Breast cancer (sister and two paternal aunts), lung cancer (paternal uncle)	wt	wt	wt	wt	wt	nd	-
Probands/families with mesothelioma (without melanoma) and features of inherited cancer predisposition									
30 (F)	Epithelioid pleural mesothelioma (46)	Mesothelioma (mother)	wt	wt	wt	wt	wt	nd	-
31 (M)	Biphasic peritoneal mesothelioma(49)	Mesothelioma (three sisters and brother)	nd^,*	wt	wt	nd*	nd*	nd*	-
32 (M)	Biphasic pleural mesothelioma (53)	Mesothelioma (paternal uncle and two cousins), leukemia (twin brother of the father)	wt	wt	wt	wt	wt	nd	-
33 (M)	Epithelioid pleural mesothelioma (55)	Mesothelioma (paternal grandmother), prostate cancer (father)	wt	wt	wt	wt	wt	nd	-
34 (M)	Epithelioid pleural mesothelioma (68)	Mesothelioma (sister and nephew)	wt	wt	wt	wt	wt	nd	-
35 (M)	Epithelioid pleural mesothelioma (70)	Mesothelioma (both parents), papillary thyroid carcinoma (daughter)	wt	wt	wt	wt	wt	nd	-
36 (M)	Sarcomatoid mesothelioma (66)	Mesothelioma (father and cousin)	wt	wt	wt	wt	wt	nd	-
37 (M)	Mesothelioma Neuroblastoma	Negative	nd^,*	nd*	nd*	nd*	nd*	nd*	-
38 (F)	Epithelioid mesothelioma (28) Hodgkin linfoma (18)	Negative	wt	wt	wt	wt	wt	nd	-
39 (M)	Epithelioid mesothelioma Basalioma	Negative	nd^,*	nd*	nd*	nd*	nd*	nd*	-
40 (F)	Epithelioid mesothelioma (69)	Lung cancer (uncertain diagnosis,	wt	nd	nd	nd	nd	nd	-

		mother)							

692   wt (wild type), nd (not done)

693   ^IHC: normal nuclear expression; *Germline DNA not available or very scanty

694

695   § This patient was reported by Pastorino et al. (2008) [1]. The authors considered this variant as possibly damaging, using a single prediction tool (Polyphen). We have integrated
696 this *in silico* analysis using six prediction tools, i.e. Mut taster, SIFT, Provean, Mut assessor, Condel, and Phyre2. To assess a possible aberrant splicing we used Human Splicing
697 Finder, MaxEnt, BDGP, NetGene2, GeneScan, FGENESH 2.6 and FSPLICE 1.0. Four out of seven disease-causing prediction tools reported the p.Thr77Ala variant as neutral.
698 No data are reported for LOH, IHC and segregation analysis. Moreover, none of the 7 splice-site prediction tools has shown the creation of alternative splice sites for this variant.
699 Thus, we concluded that the p.Thr77Ala variant should be considered as a VUS and the patient was considered eligible for mutation analysis in other genes.

700

701 [1] Pastorino L, Bonelli L, Ghiorzo P, Queirolo P, Battistuzzi L, Balleari E, Nasti S, Gargiulo S, Gliori S, Savoia P, Abate Osella S, Bernengo MG, Bianchi Scarrà G. 2008.
702 CDKN2A mutations and MC1R variants in Italian patients with single or multiple primary melanoma. Pigment CellMelanomaRes 21(6):700-9. doi: 10.1111/j.1755-
703 148X.2008.00512.x.

704

705

706

4

Supplementary Figure 1- *BAP1* germline duplications
The proband is denoted by a black arrow. A plus symbol indicates individuals with germline variant. A grey arrow denotes the mutation in the electropherogram. PB (peripheral blood).

A. Family ID16. Pedigree is reported in Figure 1B. A1. Electropherogram: a new germline 5bp duplication (c.-594dupCCCGT) in the *BAP1* promoter region was found in the proband (IV-1 PB), in a sister (IV-2 PB), in her mother (III-5 PB) and in her maternal aunt (III-6 PB). This duplication is *in cis* with the p.Asp567Ala missense variant.

B. Family ID4. B1. Pedigree: the proband (II-1) had cutaneous melanoma and breast cancer, the brother (II-2) had papillary renal cell carcinoma type 2, the father (I-1) died for mesothelioma and the mother (I-2) had breast cancer. B2. Electropherogram: a new germline 19bp duplication (c.-247dupCCTTCGCCCCGTCCCTCC) in the *BAP1* promoter region was found in the proband (II-1 PB). No specimens from relatives were available for segregation analysis.

Supplementary Figure 1

A Family ID16

A1

BAP1 c.-594dupCCCGT

B Family ID4

B1

skin melanoma
mesothelioma
kidney cancer
breast cancer
other tumors

B2

BAP1 c.-247dupCCTTCGCCCCCGTCCCTCC

6

Supplementary Figure 2 - Predicted structure of BAP1 protein

Predicted structure of BAP1 protein according to Protein Homology/analogY Recognition Engine v 2.0 (Phyre2). The yellow arrows indicate the position of D567 (a) or the mutant A567 (b).

The wild type negative charged D567 seems to localize at the interface with the ubiquitin carboxy-terminal hydrolase domain (residues 1-240) depicted in dark to light blue with the catalytic sites Q85, C91, H169 and D184 shown in white. Known domains are indicated with different colours according to their position: HCFC1 binding motif in green (residues 363-366), the long alpha helix of the BRCA1 binding domain in orange (residues 629-659/669) and the Nuclear Localization Signal (NLS, residues 717-722) in red.

The mutant hydrophobic A567 is predicted buried within the globular portion of the protein and the relevant domains of the BAP1 protein seem to assume a different position.

Supplementary Figure 2

a)

b)

Supplementary Table I – Probands clinical data

Family ID (sex)	Age at diagnosis	Proband's tumors	Other clinical information	Asbestos exposure	Follow-up (years)	Family history
		**Cases/families with the association of cutaneous melanoma and mesothelioma**				
1 (F)	33	Cutaneous melanoma of the left leg (superficial spreading melanoma, 0.46 mm Breslow thickness, Stage IA)	No dysplastic nevi, 10-50 melanocytic nevi, Fitzpatrick skin phototype II	Not registered (mother)	No relapse (5)	Mesothelioma (mother), breast cancer (maternal grandmother)
2 (F)	43	Cutaneous melanoma of the abdomen (superficial spreading melanoma, 0.20 mm Breslow thickness, Stage pT1)	High grade naso pharynx carcinoma with lymph node metastasis (24) Rectal carcinoma (56)	Not registered (father)	Exitus for metastatic rectal carcinoma (14)	Mesothelioma (father) and other tumors in the paternal family
3 (F)	41	Cutaneous melanoma (superficial spreading melanoma, 1.00 mm Breslow thickness Stage IB)	Previous excision of several dysplastic nevi Fitzpatrick skin phototype II	Possible occupational exposure as cotton weaver for 5 years (mother)	No relapse (10)	Mesothelioma and cutaneous melanoma (mother)
4 (F)	30	Cutaneous melanoma of the left leg (superficial spreading melanoma, Breslow thickness not available)	Breast cancer (58)	Not registered (father)	Subcutaneous metastasis (35)	Mesothelioma (father), breast cancer (mother), papillary renal cell carcinoma type 2 (brother)
5 (F)	53	Cutaneous melanoma of the ear (53) (superficial spreading melanoma, 1.1 cm Breslow thickness Stage pT2a), ephitelioid pleural mesothelioma (53), cutaneous melanoma of the scalp (57)	Meningioma (37)	No exposure to asbestos could be identified, but residential history was incomplete	No relapse (5)	Gastric cancer (mother), basal cell carcinoma of the skin (brother)
6 (M)	65	Epithelioid mesothelioma	-	No interview available	(3)	Melanoma (brother), colon cancer (father)
		**Cases/families with melanoma (without mesothelioma) and with familiarity for *BAP1* associated tumors** (i.e. early onset melanoma, either ocular or cutaneous, multiple primary tumors, positive family history, development of other tumors except mesothelioma)				

Family ID (sex)	Age at diagnosis	Proband's tumors	Other clinical information	Asbestos exposure	Follow-up (years)	Family history
7 (F)	25 and 30	Bilateral ocular melanoma (uvea)	*In situ* ductal breast tumor (40)	-	No relapse (23)	Acustic neurinoma (sister), larynx tumor (father and two paternal relatives), bladder tumor (mother)
8 (M)	31 and 33	Ocular melanoma (iris-uvea)	No dysplastic nevi <10 melanocytic nevi Fitzpatrick skin phototype III	-	No relapse (5)	Negative
9 (F)	67 and 72	Ocular melanoma (uvea) and cutaneous melanoma (1st Clark level)	Thyroidectomy for goiter (58) Schwannoma of the auditory nerve - facial dx (71)	-	No relapse (1)	Cutaneous melanoma (daughter and niece), lung cancer (father)
10 (F)	63	Ocular melanoma (choroid)	Bilateral breast cancer (60, 65)	-	No relapse (7)	Breast cancer (sister, maternal cousin, paternal aunt), renal cancer (maternal aunt)
11 (F)	46	Cutaneous melanoma of the abdomen (superficial spreading melanoma, 0.20 mm Breslow thickness, Stage IA)	No dysplastic nevi, <10 melanocytic nevi	-	No relapse (4)	Ocular melanoma (uveal, father), colon cancer
12 (F)	43	Two synchronous cutaneous melanomas of left and right leg (superficial spreading melanoma, 0.20 and 0.28mm Breslow thickness, Stage IA)	No dysplastic nevi, <10 melanocytic nevi, Fitzpatrick skin phototype III Renal cell cancer, clear cells with focal areas of papillary architecture (41)	-	No relapse (4)	Negative
13 (M)	65	Lentigo maligna melanoma of the right forearm (0.23mm Breslow thickness, Stage IA)	No dysplastic nevi Fitzpatrick skin phototype II	-	No relapse (13)	Cutaneous melanoma (daughter, nephew), renal cell carcinoma (brother)
14 (M)	54 and 58	Three cutaneous primary melanomas: lentigo melanoma of the left cheekbone (Stage 0); two synchronous cutaneous melanomas of the left shoulder and lumbar region (superficial spreading melanoma 0.65 mm Breslow thickness, Stage IA and 2.34 mm Breslow thickness, Stage IIIB)	No dysplastic nevi, >50 melanocytic nevi, Fitzpatrick skin phototype I	-	Exitus for metastatic melanoma (5)	Cutaneous melanoma (mother), renal cell carcinoma + uterus cancer + breast cancer (sister), pancreatic carcinoma, liver, prostate

10

Family ID (sex)	Age at diagnosis	Proband's tumors	Other clinical information	Asbestos exposure	Follow-up (years)	Family history
15 (F)	34 and 40	Two cutaneous primary melanomas of the supraclavear left and left breast regions (superficial spreading melanomas, 0.64 and 0.23 mm Breslow thickness, Stage IA)	No dysplastic nevi, > 50 nevi melanocytic nevi, Fitzpatrick skin phototype III	-	No relapse (10)	Cutaneous melanoma (paternal uncles), renal cell cancer (father), lung cancer (two paternal uncles)
16 (F)	24 and 25	Two cutaneous amelanotic melanomas of the left shoulder and of the right arm (nodular melanoma, 1.80 mm Breslow thickness, Stage IB and superficial spreading melanoma, 0.30 mm Breslow thickness, Stage IA)	No dysplastic nevi, >50 clinical atypical melanocytic nevi Fitzpatrick skin phototype II	-	No relapse (9)	Cutaneous melanoma (paternal uncle), non-Hodgkin cutaneous lymphoma (low grade, CD20+, mother)
17 (F)	31 and 33	Two cutaneous primary melanomas (superficial spreading melanoma, Breslow thickness not available)	-	-	Not available	Cutaneous melanoma (father)
18 (F)	56 and 57	Two cutaneous melanomas (superficial spreading melanoma, Breslow thickness not available)	-	-	Not available	Cutaneous melanoma (father)
19 (F)	67	Two synchronous cutaneous melanomas of the right hip and of the right arm (superficial spreading melanoma, 0.20 mm Breslow thickness, Stage IA and melanoma *in situ*, Stage 0)	No dysplastic nevi, <10 melanocytic nevi Fitzpatrick skin phototype II Facial basal cell carcinoma (69)	-	No relapse (4)	Cutaneous melanoma (sister), breast cancer, CNS, prostate cancer
20 (M)	20	Cutaneous melanoma of left leg (superficial spreading melanoma, 0.52 mm Breslow thickness, Stage IA)	No dysplastic nevi, <10 melanocytic nevi Fitzpatrick skin phototype II	-	No relapse (3)	Cutaneous melanoma (mother), breast and colon cancer
21 (M)	24	Cutaneous melanoma of the abdomen (superficial spreading melanoma, 0.26 mm Breslow thickness, Stage IA)	No dysplastic nevi, <10 melanocytic nevi, Fitzpatrick skin phototype II	-	No relapse (6)	Cutaneous melanoma (mother), prostate cancer, vulvar cancer
22 (F)	27	Cutaneous *in situ* melanoma on the back (Stage 0)	Dysplastic nevi, >50 melanocytic nevi, Fitzpatrick skin phototype II	-	No relapse (5)	Cutaneous melanoma (father), prostate cancer
23 (M)	32	Cutaneous melanoma of the sternum (nodular melanoma, 2.10 mm Breslow thickness, Stage IIB)	No dysplastic nevi, <10 melanocytic nevi, Fitzpatrick skin phototype II	-	No relapse (3)	Cutaneous melanoma (sister)

11

Family ID (sex)	Age at diagnosis	Proband's tumors	Other clinical information	Asbestos exposure	Follow-up (years)	Family history
24 (F)	35	Cutaneous melanoma of the right scapula (superficial spreading melanoma, 0.90 mm Breslow thickness, Stage IB)	No dysplastic nevi, 10-50 melanocytic nevi, Fitzpatrick skin phototype II	-	No relapse (3)	Cutaneous melanoma + thyroid cancer (father)
25 (F)	39	Cutaneous melanoma (superficial spreading melanoma, Breslow thickness not available)	-	-	Not available	Cutaneous melanoma + colon cancer (brother)
26 M	82	Cutaneous melanoma of the back, (0.83 mm Breslow thickness, 3rd Clark level)	Fitzpatrick skin phototype III, chronic sun exposure	-	No relapse (1)	Cutaneous melanoma (brother), pancreatic cancer (sister)
27 (M)	38 to 52	Ten cutaneous primary melanomas	Testicular teratoma (27) multinodular goiter	-	Not available	Breast cancer (mother)
28 (M)	57 and 58	Three cutaneous primary melanomas	Lipoma (27) Adrenal cortex adenoma (53)	-	Not available	Prostate cancer (father), liver cancer (paternal uncle and paternal grandfather)
29 (M)	61	Cutaneous melanoma of the back (4.6mm Breslow thickness, 5th Clark level)	Fitzpatrick skin phototype III, sun exposure	-	No relapse (2)	Breast cancer (sister and two paternal aunts), lung cancer (paternal uncle)
Cases/families with mesothelioma (without melanoma) and with familiarity for *BAP1* associated tumors (other mesothelioma cases among relatives, development of other tumors except melanoma)						
30 (F)	46	Epithelioid pleural mesothelioma	-	Household (low)	No relapse (10)	Biphasic mesothelioma (mother), lung cancer (father), bone cancer (maternal aunt), bowel cancer (maternal grandmother)
31 (M)	49	Biphasic peritoneal mesothelioma	-	Household	Exitus (7 months)	Mesothelioma (three sisters and brother)
32 (M)	53	Biphasic pleural mesothelioma	-	Household (low)	Exitus (5)	Mesothelioma (paternal uncle and two cousins), leukemia (twin brother of the father)
33 (M)	55	Epithelioid pleural mesothelioma	-	Possible occupational/ household (low)	Not available	Mesothelioma (paternal grandmother), prostate cancer (father)
34 M	68	Epithelioid pleural mesothelioma	-	No interview available	No relapse (1)	Mesothelioma (sister and nephew)

Family ID (sex)	Age at diagnosis	Proband's tumors	Other clinical information	Asbestos exposure	Follow-up (years)	Family history
35 (M)	70	Epithelioid pleural mesothelioma	-	Household (low)	No relapse (3)	Mesothelioma (both parents), papillary thyroid carcinoma (daughter)
36 (M)	66	Sarcomatoid mesothelioma	-	Possible occupational exposure as baker 1962-1974 and residential exposure 1947-1977 (in Stradella)	No relapse (2)	Mesothelioma (father and cousin), lung cancer (paternal uncle)
37 (M)	Not available	Mesothelioma, neuroblastoma	-	Possible occupational exposure as pipe-fitter 2003-2004, radiotherapy 1985 (for neuroblastoma)	Not available	Negative
38 (F)	28 and 18	Epithelioid mesothelioma, Hodgkin linfoma	-	Para-occupational exposure 1985-1993 (father boiler and pipe-fitter), radiotherapy 2003 (for NHL)	Exitus (5 months)	Lung cancer (maternal cousin), leukemia (maternal cousin's daughter)

13

Family ID (sex)	Age at diagnosis	Proband's tumors	Other clinical information	Asbestos exposure	Follow-up (years)	Family history
39 (M)	Not available	Epithelioid mesothelioma, basalioma	-	Possible occupational exposure as house-builder 1944 and 1951-1983	Not available	Negative
40 (F)	69	Epithelioid mesothelioma with metastasis on the scalp	-	Possible occupational exposure as cotton warper 1950-1983 and household exposure 1982 (removal of asbestos-cement roofing)	No relapse (12)	Lung cancer (uncertain diagnosis, mother)

Supplementary Table II – Primer sequences for the amplification of *BAP1, CDKN2A, CDK4, MITF, TERT, POT1* genes.

GENE	PRIMERS	SEQUENCES	AMPLICON LENGTH (bp)
	BAP1_prom1F BAP1_prom2R	GCTTTAGTCGTTGACACAGG GGGAGAAAAGGCTCTTACCG	1040
BAP1	BAP1_ex1-3F BAP1_ex1-3R	GAAGACGAGCCCAGAGG CGTAGGGTTCCTGGCACTGTC	619
	BAP1_ex4bisF BAP1_ex4bisR	TTCATAAGGAGACTGGGTGGA GACACAGAGAGTGGACTCAG	597
	BAP1_ex5F BAP1_ex5R	TGGGTATTTGGTAGGTGCTTG CTTTCCCCGCAACTGCATC	486
	BAP1_ex6-7F BAP1_ex6-7R	TCTGTGTTCCTTCCGATTCC GGTCGGGCAATATGGTGTAG	562
	BAP1_ex8F BAP1_ex8R	CGACCAGCTCCTGATTCC CCTGATCTTGCCAGATTCACC	313
	BAP1_ex9F BAP1_ex9R	CAGGTCTGCTGGTTCACTTCC CTATTCTCCCTCCCCACTCC	531
	BAP1_ex10F BAP1_ex10R	GGAAAGGTGGGACTTGGAG AGGGGCCTGTGGTAACAGC	531
	BAP1_ex11F BAP1_ex11R	GGCTGGGCTGTTCTTCTCTG GGAACCACATGGGAAAATTGC	374
	BAP1_ex12F BAP1_ex12R	CAGTGTAAGTGGGTGGCAGC CAAACTCCGCAGGTGCTCAAC	425
	BAP1_ex13F BAP1_ex13R	GGCTTAGCATGGCTAGTTCAAG GCAGGACACTTTGTGGTCAC	715
	BAP1_ex14F BAP1_ex14R	CTTGGACTGGCTCACTGGC GAAAGTCTTCTGGCACATGGC	408
	BAP1_ex15-16F BAP1_ex15-16R	GAAGACTTTCTGGGTTGGGTGG CCTGCGAAGAGGTAGAGACC	591
	BAP1_ex17F BAP1_ex17R	CCTGAGGCTTGAGCAGACCTTG GCTGTGCCCCAACTCCAGATG	466
CDKN2A	p16_ex 1α F p16_ex 1α R	GAAGAAAGAGGAGGGGCTG GCGCTACCTGATTCCAATTC	340
	p14_ex 1β F p14_ex 1β R	CGCTCAGGGAAGGCGGGTG ACCAAACAAAACAAGTGCCG	407
	p16_ex 2F p16_ex 2R	GGGGCTTGTGTGGGGGTCTG GTGCTGGAAAATGAATGCTCTG	483
	p16_ex 3F p16_ex 3R	CGGTAGGGACGGCAAGAGAG CCTGTAGGACCTTCGGTGACTGA	179
CDK4	CDK4_ex 2F CDK4_ex 2R	GCTGCAGGTCATACCATCCT ATCATCACACCCCACCTATAGG	372
MITF	MITF_ex 9F MITF_ex 9R	TGTGCTCTGCCTATTTCAGTG AAGAAACCCCTTCAGGTAAGTT	340
TERT	Prom F Prom R	GTCCTGCCCCTTCACCTT AGCACCTCGCGGTAGTGG	488
POT1	POT1_ex10F POT1_ex10R	AGCTGATATTCAACCACACTCGT GCACAAAAGGCTAGGGAACTATC	435

1

Supplementary Table III – *In silico* analyses of *BAP1* exonic mutations

BAP1 missense variants (exon) Genomic position on chr3				[Ref] Case ID Tumors in patients with *BAP1* variants (Age of diagnosis) and in untested family members									
1000G ExAC	Mut taster	SIFT	Provean	PolyPhen HumVar (HumDiv)	Mutation assessor	Condel	Phyre2	LOH	IHC	Segregation analysis	Splice site prediction	Conclusion	
c.41T>A (**p.Leu14His**) (exon 2) 3:52443756A>T				[23] NCI-1326 RCC (40, 44, 46, 54, 57) in carriers / RCC in other family members									
-	0,9999 diseasecausing	0,000 damaging	-6,04 deleterious	1,00 probablydamaging (1,00)	2,48 medium impact	0,55568 deleterious	likely to affect function (highest score)	clear LOH in proband's tumors	Loss of BAP1 proteinexpression	Variant cosegregates with the RCC predisposition (LOD score 1.2)	No alterations	Disease causing	
c.277A>G (**p.Thr93Ala**) (exon 5) 3:52442072T>C				[22] A Adenocarcinoma of Unknown Primitive Tumor, Breast Ca x3, RCC (37, 39, 40, 47, 47), Cervical Ca, CaSU in carriers / Esophagus Ca x2, Head and Neck Carcinoma, Lung Ca, Breast Ca in other family members									
-	0,9999 diseasecausing	0,001 damaging	-4,56 deleterious	0,989 probablydamaging (0,999)	3,875 higt impact	0,73011 deleterious	likely to affect function (highest score)	RCC sample from the index case shows LOH for the 3pter-14.1 chromosomal region (genomic position 0-64Mb) as the unique acquired large genomic deletion in this tumor	Loss of BAP1 proteinexpression	Variant segregates with RCC (Segregation analysis based on identity by descend - IBD-)	New cryptic acceptor site (Human Splicing Finder, MaxEnt)	Disease causing	

1

BAP1 missense variants (exon) Genomic position on chr3				[Ref] Case ID Tumors in patients with BAP1 variants (Age of diagnosis) and in untested family members									
1000G ExAC	Mut taster	SIFT	Provean	PolyPhen HumVar (HumDiv)	Mutation assessor	Condel	Phyre2	LOH	IHC	Segregation analysis	Splice site prediction	Conclusion	
c.299T>C (**p.Leu100Pro**) (exon 5) 3:52442050A>G				[11] UM (45, 56), Cholangiocarcinoma (71), Urothelial Carcinoma (48) in carries / RCC, Brain Ca, Leukemia, Uterine Ca in other family members									
-	0,9999 diseasecausing	0,000 damaging	-6,62 deleterious	1,00 probablyda maging (1,00)	3,77 higt impact	0,69994 deleterious	likely to affect function (highest score)	LOH of 8 markers, consistent with monosomy 3	nd	Variant segregates with UM (mother-son)	No alterations	Disease causing	
c.539T>C (**p.Leu180Pro**) (exon 7) 3:52441231A>G				[16] FUM124 UM (60), CM (72), MM (71), BCC (56, 65, 68) in carriers / Breast Ca x2, BCC x6, SCC, Non-melanoma Skin Ca, CM x2, Prostate Ca, Uterine Ca, Liposarcoma, Melanoma (meningeal), Cervical Ca, CaSU x3, MM, GI TractCancer in otherfamilymembers									
-	0,9999 diseasecausing	0,000 damaging	-6,90 deleterious	1,00 probablyda maging (1,00)	3,725 higt impact	0,70362 deleterious	likely to affect function (highest score)	nd	nd	Variant does not unconditionally track with the disease	No alterations	Disease causing	
c.1327A>T (**p.Asn443Tyr**) (exon 13)3:52437834T>A				[14] 16 UM in carrier / CaSU in otherfamilymembers									
-	0,9997 diseasecausing	0,005 damaging	-0,89 neutral	0,855 possiblyda maging (0,994)	0,55 neutral	0,46382 neutral	unlikely to affect function (highest score)	nd	nd	no data	No alterations	VUS	

2

BAP1 missense variants (exon) Genomic position on chr3				[Ref] Case ID Tumors in patients with BAP1 variants (Age of diagnosis) and in untested family members								
1000G ExAC	Mut taster	SIFT	Provean	PolyPhen HumVar (HumDiv)	Mutation assessor	Condel	Phyre2	LOH	IHC	Segregation analysis	Splice site prediction	Conclusion
c.1445C>T, **p.Ser482Leu** (exon 13)3:52437716G>A				[14] 19 UM in carrier / CM, Lung Ca x3 in otherfamilymembers								
- 1 het 60.463 All	0,9999 diseasecausing	0,104 tolerated	-0,71 neutral	0,057 benign (0,760)	0,895 low impact	0,472555 neutral	unlikely to affect function (highest score)	nd	nd	no data	New acceptor site (MaxEnt, NetGene2)	VUS
c.1708C>G **p.Leu570Val** (exon 13)3:52437453G>C				[21] UM (18, 46, 62), CM (27, 27, 33), MM (47), Peritoneal MM (84), Lung Ca (46), Paraganglioma (42), Breast Ca (75), Malignant Fibrous Histiocytoma (45) in carriers / Prolactinoma in other family member								
-	0,6937 diseasecausing	0,054 tolerated	-0,52 neutral	0,016 benign (0,075)	0,695 neutral	0,469014 neutral	unlikely to affect function (highest score)	LOH in UM and PGL	nd	Variant segregates in this multi-cancer family	Activation of a cryptic donor site 22bp before the end of the exon (Human Splicing Finder, MaxEnt, BDGP, NetGene2, GeneScan,FGENESH 2.6, FSPLICE 1.0)	Disease causing
c.518A>G (**p.Tyr173Cys**) (exon 7)3:52441252T>C				[17] UM (72), MM, adenocarcinoma in carriers / MM x2, RCC, ALL in otherfamilymembres								

3

BAP1 missense variants (exon) Genomic position on chr3				[Ref] Case ID Tumors in patients with *BAP1* variants (Age of diagnosis) and in untested family members								
1000G ExAC	**Mut taster**	**SIFT**	**Provean**	**PolyPhen HumVar (HumDiv)**	**Mutation assessor**	**Condel**	**Phyre2**	**LOH**	**IHC**	**Segregation analysis**	**Splice site prediction**	**Conclusion**
-	0,9999diseasecausing	0,000damaging	-7,75 deleterious	0,999probablydamaging(1,000)	3,27medium	0,662034deleterious	likely to affect function (highest score)	nd	Loss of nuclear BAP1 labeling in adenocarcinoma but nuclear labeling for BAP1 was retained in the MM (No UM specimen available)	no data	Activation of an exonic cryptic donor site (Human Splicing Finder, MaxEnt)	Disease causing
c.233A>G(**p.Asn78Ser**) (exon 4) 52442512T>C				[6] ABS2570 Kidney Ca, MM in carriers / Gastic Ca x4 in otherfamilymembres								
-	0,9999diseasecausing	0,06tolerated	-3,80 deleterious	0,608possiblydamaging(0,767)	0,7 neutral	0,442072neutral	unlikely to affect function (high score)	nd	nd	no data	Activation of an exonic cryptic donor site (Human Splicing Finder, MaxEnt, BDGP, NetGene2, GeneScan, FSPLICE); Activation of an exonic acceptor site, with one or more cryptic branch point(s) (Human Splicing Finder	Disease causing
c.1748C>T (**p.Ser583Leu**) (exon 14)3:52437296G>A				[6] ABS3313 MM (67), BCC in carrier / CM in otherfamilymember								

4

BAP1 missense variants (exon) Genomic position on chr3				[Ref] Case ID Tumors in patients with BAP1 variants (Age of diagnosis) and in untested family members								
1000G ExAC	Mut taster	SIFT	Provean	PolyPhen HumVar (HumDiv)	Mutation assessor	Condel	Phyre2	LOH	IHC	Segregation analysis	Splice site prediction	Conclusion
- 1 het 6503 All	0.9871disease causing	0,38tolerated	-0,84 neutral	0,001benign (0,001)	0,345 neutral	0,451540neutral	unlikely to affect function (high score)	nd	nd	no data	New acceptor site (MaxEnt)	VUS
c.1147C>T (**p.Arg383Cys**) (exon 12)3:52438572G>A				[6] ABS3023 MM in carrier / Breast Ca in otherfamilymember								
1 het 6502 All5 het (4.471e-05)	0,9999disease causing	0,03 damaging	-2,51 deleterious	0,990proba blydamaging(1,000)	1,845 low impact	0,489999neutral	unlikely to affect function (high score)	nd	nd	no data	No alterations	VUS
c.1700A>C (**p.Asp567Ala**) (exon 13) 52437461T>G				[this work] ID16 CM (28, 28), Cutaneous lymphoma NH-B (57) in carriers /								
-	0,9999 diseasecausing	0,003 damaging	-1,71 neutral	0,696 possiblyda maging (0.976)	0,975 low impact	0,48069 neutral	unlikely to affect function (high score)	Melanoma sample show a decreased amount of the paternal allele, suggesting the loss of the wild type allele	Two different melanomas of the index case show the normal BAP1 expression in the nucleus	Variant does not unconditionally track with the disease	No alterations	VUS
More frequent missense variants reported in ExAc (heterozygote, homozygote and total individuals of the population at higher frequency)												

5

BAP1 missense variants (exon) Genomic position on chr3				[Ref] Case ID Tumors in patients with BAP1 variants (Age of diagnosis) and in untested family members								
1000G ExAC	Mut taster	SIFT	Provean	PolyPhen HumVar (HumDiv)	Mutation assessor	Condel	Phyre2	LOH	IHC	Segregation analysis	Splice site prediction	Conclusion
c.121G>A (**p.Gly41Ser**) (exon 3) 3:52443571C>T				nn								
78 het 2.506 Asn	0,9999 diseasecausing	0,369 tolerated	-3,12 deleterious	0.078 benign (0,078)	0,049 neutral	0,458715 neutral	unlikely to affect function (high score)	-	-	-	New cryptic donor site (MaxEnt)	VUS / Likely benign
c.869A>G (**p.Asn290Ser**) (exon 10) 3:52439843T>C				nn								
54 het 5.772 Lat	0,9998 poly-morphism	1,000 tolerated	-0,57 neutral	0.000 benign (0,000)	neg score neutral	0,332615 neutral	unlikely to affect function (highest score)	-	-	-	No alterations	Likely benign
c.1201T>G (**p.Tyr401Asp**) (exon 12)3:52438518A>C				nn								
20 het 60.059 All	0,9999 diseasecausing	0,537 tolerated	-2,12 neutral	0.186 benign (0,437)	0,095 neutral	0,491095 neutral	unlikely to affect function (highest score)	-	-	-	No alterations	VUS / Likely benign
c.1786A>G (**p.Ser596Gly**) (exon 14) 3:52437258T>C				nn								

6

BAP1 missense variants (exon) Genomic position on chr3				[Ref] Case ID Tumors in patients with BAP1 variants (Age of diagnosis) and in untested family members								
1000G ExAC	Mut taster	SIFT	Provean	PolyPhen HumVar (HumDiv)	Mutation assessor	Condel	Phyre2	LOH	IHC	Segregation analysis	Splice site prediction	Conclusion
740 het 30 hom 5.201 Afr	0,9999 poly-morphism	0,393 tolerated	-0,01 neutral	0.000 benign (0,000)	neg score neutral	0,390318 neutral	unlikely to affect function (highest score)	-	-	-	No alterations	Benign
c.1838C>T (p.Thr613Met) (exon 14) 52437206G>A				nn								
128 het 1 hom 5.202 Afr	0,9999 poly-morphism	0,063 tolerated	-0,34 neutral	0.001 benign (0,001)	0,000 neutral	0,426829 neutral	unlikely to affect function (highest score)	-	-	-	No alterations	Benign

This table was modified from Rai et al. 2016 [16]

RCC renal cell carcinoma, CaSU, Cancer site unknown, UM uveal melanoma, MM malignant mesothelioma, CM cutaneous melanoma, BCC basal cell carcinoma, ALL Acute lymphocytic leukemia, LOH loss of heterozygosity, IHC immunohistochemistry, Nd not done, NN none, VUS variant of unknown significance.